Consumer Health News and Research

RSS

Validic Labs launched to bridge the gap between healthcare companies and mHealth data producers

Validic, pioneer of the first truly inclusive mobile health marketplace, announced today the latest innovation to its data-leveraging platform. Validic has launched Validic Labs in an effort to further bridge the gap between mHealth data producers and healthcare companies. Validic Labs facilitates a simple connection between the app and device developers and the healthcare system in an effort to foster faster, more productive healthcare innovation on both sides.

18 Feb 2014

CVS' tobacco move brings praise, analysis as marketing move

Some are praising CVS' decision not to sell tobacco products while others say it's a marketing ploy meant to position the drugstore keenly in the middle of consumer health care.

7 Feb 2014

Therapath signs contract with United Healthcare to provide neuropathology services

Therapath LLC, the leader in comprehensive diagnostic and consultative neuropathology laboratory services, has signed a national contract with United Healthcare, a division of UnitedHealth Group (NYSE: UNH), to provide the pathology analysis for these specialty services.

29 Jan 2014

Pfizer announces results from Phase 3 study of ALO-02 in patients with chronic low back pain

Pfizer Inc. (NYSE: PFE) announced today top-line results from a Phase 3 study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic low back pain.

24 Jan 2014

Takeda expands commercial platform in Israel

Takeda Pharmaceuticals International GmbH today announced further expansion of its commercial platform with the establishment of its wholly-owned subsidiary in Israel. Together with Algeria, Ecuador, Peru, Singapore and Vietnam, Israel is the sixth sales entity Takeda has opened this year to reinforce its platform in growth markets.

18 Dec 2013

TELUS Health to offer Medworxx Patient Flow Platform to customers

Medworxx Solutions Inc. today announced that TELUS Health will now offer customers the Medworxx Patient Flow Platform, enabling health care practitioners to better analyze and monitor patient health in an acute care environment. Comprised of Medworxx Clinical Criteria, Bed Management System, and Forms and Assessments, the platform is available as part of TELUS Health's suite of technology solutions.

16 Dec 2013

Virginia Health Information publishes 2013 Health Care Pricing Report

As the price of health care increases, employers struggle to control costs and maintain employee health care benefits. One strategy increases the amount employees pay in deductibles or co-pays. With more money coming out of their pockets, information on the costs of care can help consumers make more informed health care purchasing decisions.

10 Dec 2013

Silverlink, UnitedHealthcare recognized for increasing colorectal cancer screenings among minorities

Silverlink Communications, Inc., and UnitedHealthcare's program to increase colorectal cancer screenings among minority populations earned the companies a 2013 Outstanding Leadership in Population Health Award from the Care Continuum Alliance at the recent CCA Forum 2013.

6 Dec 2013

Pfizer's Polish subsidiary acquires rights to Polocard from ZF Polpharma SA

Pfizer Inc. today announced that a wholly-owned Polish subsidiary of Pfizer has acquired the rights to Polocard, a low-dose aspirin (acidum acetylsalicylicum), and the leading over-the-counter brand for heart attack prevention in Poland, from ZF Polpharma SA.

3 Dec 2013

State exchange news: Oregon's 'epic failure'; Kansas' next steps on canceled policies; rural challenge in Minnesota

Oregon once led the country in implementing Obamacare. Now it's just about dead last. Not one person has yet enrolled in the Cover Oregon insurance exchange -; a major embarrassment to state policymakers who early on had wholeheartedly embraced the Affordable Care Act even as other states tried their best to hinder it. ... The uncertainty is leading to fears that Oregonians whose plans have been canceled as of Dec. 31 will find themselves without affordable coverage when the new year begins (Winfield Cunningham, 11/26).

27 Nov 2013

Health law outreach efforts try new controversial ads, enrollment tactics

Health law outreach efforts take on new wrinkles -- Colorado officials launch controversial ads geared toward women and Enroll America changes how it tries to get people to sign up for health coverage. In the meantime, Republicans are releasing their own set of ads mocking the law.

13 Nov 2013

First Edition: November 13, 2013

Today's headlines include not-so-positive predictions about whether healthcare.gov will be fully functional by the end of November.

13 Nov 2013

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant.

12 Nov 2013

FDA approves Prior Approval Supplement for EMBEDA Extended Release Capsules CII

Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved a Prior Approval Supplement for EMBEDA (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII.

4 Nov 2013

Pfizer to continue development of Remoxy Extended-Release Capsules CII

Pfizer Inc. announced today that, having achieved technical milestones related to manufacturing, it will continue the development program for Remoxy (oxycodone) Extended-Release Capsules CII.

22 Oct 2013

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Pfizer Inc. (NYSE:PFE) announced top-line results from two phase 3b, placebo-controlled studies with Lyrica® (pregabalin) Capsules CV in patients with fibromyalgia (FM) and painful diabetic peripheral neuropathy (DPN), respectively.

19 Oct 2013

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Pfizer Inc. (NYSE:PFE) announced today that the European Commission approved updates to the Summary of Product Characteristics (SmPC) for the company's pneumococcal conjugate vaccine Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), regarding its use in certain populations at high risk of pneumococcal disease.

18 Oct 2013

Sanofi's Nasacort Allergy 24HR nasal spray receives FDA approval for over-the-counter use

Sanofi announced today that the U.S. Food and Drug Administration approved Nasacort Allergy 24HR nasal spray as an over-the-counter treatment for seasonal and year-round nasal allergies in adults and children 2 years of age and older.

12 Oct 2013

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

Pfizer Inc. announced today top-line results from two Phase 3 clinical trials of tofacitinib, a novel, oral Janus kinase inhibitor that is being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis: OPT Compare (A3921080) and OPT Retreatment (A3921111).

10 Oct 2013

Research roundup: Health law's effects on consumer spending; Mass. experience finds increased use of laparoscopic surgery

The authors find that average out-of-pocket spending is expected to decrease for all groups considered in the analysis, although decreases in out-of-pocket spending will be largest for those who would otherwise be uninsured.

5 Oct 2013